Table 14Applying the Duval et al risk of developing IE for all patients with a PCC (22 per million cases per dental procedure)

All other parameters are kept at their base case values (50 year time horizon).

Antibiotic strategyCosts per personQALYs per personIncremental cost effectiveness ratio (versus no antibiotics)
No antibiotic£2,51115.2516NA
Oral amoxicillin (strategy 1)£2,53315.2521£44,880
Oral clindamycin (strategy 2)£2,65215.2521£278,559
IV amoxicillin then oral amoxicillin (strategy 3)£2,55715.2521£90,932
Oral amoxicillin before and after (strategy 4)£2,55715.2521£91,140
IV amoxicillin, IV gent then oral amoxicillin (strategy 5b)£7,11515.2521£9,057,252
IV amoxicillin, IV gent then oral amoxicillin (strategy 5b)£2,66615.2521£305,353
IV vanco and IV gent (strategy 6)£3,21615.2521£1,387,984
IV teicoplanin and IV gent (strategy 7)£3,94015.2521£2,810,897
IV clindamycin (strategy 8)£2,85515.2521£676,892

From: 6.6 Appendix 6, De novo economic analysis

Cover of Prophylaxis Against Infective Endocarditis
Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures [Internet].
NICE Clinical Guidelines, No. 64.
Centre for Clinical Practice at NICE (UK).
Copyright © 2008, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of the Institute.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.